about
Genetic research on biospecimens poses minimal riskTowards Equity in Health: Researchers Take StockThe 2008 Declaration of Helsinki - first among equals in research ethics?Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studiesPlacebo use in vaccine trials: recommendations of a WHO expert panelEvaluating the risks of clinical research: direct comparative analysis.Research led by participants: a new social contract for a new kind of research.Disclosure of incidental findings from next-generation sequencing in pediatric genomic researchRisks of phase I research with healthy participants: A systematic reviewThe potential exploitation of research participants in high income countries who lack access to health careEvaluating the risks of clinical research.Systematic review: the effect on surrogates of making treatment decisions for others.A proposal and prototype for a Research Risk Repository to improve the protection of research participants.Systematic review: Individuals' goals for surrogate decision-making.How should we regulate risk in biomedical research? An ethical analysis of recent policy proposals and initiatives.Prisoners as research participants: current practice and attitudes in the UK.Ethical considerations of experimental interventions in the Ebola outbreak.Setting risk thresholds in biomedical research: lessons from the debate about minimal risk.Setting risk thresholds in biomedical research: lessons from the debate about minimal risk.Public participation in decision-making on the coverage of new antivirals for hepatitis C.In Defense of a Social Value Requirement for Clinical Research.Patients' priorities for treatment decision making during periods of incapacity: quantitative survey.When is research socially valuable? Lessons from the Bucharest Early Intervention Project: commentary on a case study in the ethics of mental health research.A new method for making treatment decisions for incapacitated patients: what do patients think about the use of a patient preference predictor?Individual and public interests in clinical research during epidemics: a reply to Calain : In response to: Calain P. The Ebola clinical trials: a precedent for research ethics in disasters.The goals of research during an epidemic.Why should high-income countries help combat Ebola?Do Patients Want their Families or their Doctors to Make Treatment Decisions in the Event of Incapacity, and Why?Compassionate use of experimental drugs in the Ebola outbreak - Authors' reply.Note of clarification concerning our article: controversies in the determination of death: perspectives from Switzerland.Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?Just health: meeting health needs fairly.Universal health coverage, priority setting, and the human right to health.Tackling anti-microbial resistance: ethical framework for rational antibiotic use.Is the concept of clinical equipoise still relevant to research?Substantiating the Social Value Requirement for Research: An Introduction.Determination of Death: A Discussion on Responsible Scholarship, Clinical Practices, and Public Engagement.Treatment decision making for incapacitated patients: is development and use of a patient preference predictor feasible?Use of a patient preference predictor to help make medical decisions for incapacitated patients.A framework for risk-benefit evaluations in biomedical research.
P50
Q26829694-EE9C2B15-F9F6-4D52-B157-F4F4C6DBBA55Q28119681-3BA9FA76-407F-4496-8EED-AC276F45BE8EQ28281467-880C37CE-7DF3-4706-BB50-67F98FBD8E22Q28647898-F9AAFBE8-435D-4575-9B90-312C17193A67Q34147558-7432BE78-C53F-44F9-AC8C-1E5D192EE47FQ34171698-5CA32399-21E5-4F11-9988-0761DEBE8E64Q34469468-AFAC1B1B-228E-49BB-9E2C-3E08931248E0Q36637088-B225F034-67E1-479A-92EE-E2436AAB6F7EQ36665273-0A55DA9E-64C8-42F5-B5AE-CD2038F57051Q36806612-119419C8-5510-472B-8505-1F3296899570Q37798095-F2A48661-DF5E-4C2C-BE13-5B3C4951CBDAQ37847820-7727BB5A-025F-4F62-B6B8-96BB61E483EDQ37920971-9FDB3D7C-622F-4C2E-B6C2-A3528E626DD9Q37999143-C6B99E15-648B-43B2-A915-B352684B1867Q38216336-AF2FE37F-E5E0-4377-A8CC-E98971870B99Q38222678-B9299CA4-B5D0-4A13-8FC6-F696B22B93CEQ38243093-26FB23E4-C397-4E56-A13E-51D8404FB26EQ38272693-1CCEB3DC-5C4B-4471-91E0-C04C953AC989Q38288691-2A2E37C4-370B-44CF-A50D-60025E1386A3Q38911367-274BA9AB-8170-454C-AF52-7AF1E86B9F7CQ39036003-6DC751B5-2ECD-49DE-B0BB-C2651651C89FQ39120336-40C9ABD6-BE88-43B5-81F2-0CE692E4DAD6Q39203554-8741C498-5BB0-4403-BEA8-C64A7900BAB8Q40042792-EBD1E9A9-57A4-4402-A010-E7E66AE3B831Q40071259-FFDB30CF-2EEC-4CD4-8782-C28FC5BA2B14Q40161532-824D843A-ABA2-440A-A48B-FA6D95DED871Q40191521-222A5F93-C4D7-4913-B360-D12BFCBDE783Q41698038-88A47720-715A-4187-947E-312964282496Q44094963-49FA1DF4-E70C-442C-81FD-527CE4F3AF09Q44248158-F7A3E4D5-79E5-481A-A84C-2F52223286F7Q45034975-E402FDFC-C319-476B-BEE7-917FC51AB574Q46336008-EEC2B6EB-8BC4-4E20-BA87-24E3079A4D07Q46400593-CCCA483F-F191-4C00-B3EF-8483B58054BAQ47290505-0A4CDBC5-2D02-45F4-A2A7-E2B5728DEEC3Q47568523-DA1F05E9-6F51-415B-B5C5-BFF433085BA6Q48029539-D03041B9-F09D-4F58-A0B3-F74C301EA3A1Q48054707-02110AD8-7577-4168-BE6B-B2AC04F4E734Q48085290-5637D8A3-CD5F-4F00-B995-67D1B0502BC3Q48085800-220432E5-365B-46AC-B61C-CD9804ED5267Q48643417-87F96FA4-D47A-45AB-B3D1-8362431DDDE8
P50
description
researcher (ORCID 0000-0003-1117-1975)
@en
name
Annette Rid
@en
type
label
Annette Rid
@en
prefLabel
Annette Rid
@en
P31
P496
0000-0003-1117-1975